<code id='1A45172D02'></code><style id='1A45172D02'></style>
    • <acronym id='1A45172D02'></acronym>
      <center id='1A45172D02'><center id='1A45172D02'><tfoot id='1A45172D02'></tfoot></center><abbr id='1A45172D02'><dir id='1A45172D02'><tfoot id='1A45172D02'></tfoot><noframes id='1A45172D02'>

    • <optgroup id='1A45172D02'><strike id='1A45172D02'><sup id='1A45172D02'></sup></strike><code id='1A45172D02'></code></optgroup>
        1. <b id='1A45172D02'><label id='1A45172D02'><select id='1A45172D02'><dt id='1A45172D02'><span id='1A45172D02'></span></dt></select></label></b><u id='1A45172D02'></u>
          <i id='1A45172D02'><strike id='1A45172D02'><tt id='1A45172D02'><pre id='1A45172D02'></pre></tt></strike></i>

          entertainment

          entertainment

          author:Wikipedia    Page View:15
          Adobe

          Acadia Pharmaceuticals said Monday that its approved medicine called Nuplazid failed to improve the social and emotional symptoms of schizophrenia in a late-stage clinical trial. 

          The negative outcome of the Phase 3 study represents a setback in the company’s efforts to expand the use of Nuplazid into the treatment of schizophrenia. The medicine is currently approved to treat hallucinations and delusions associated with Parkinson’s disease psychosis.

          advertisement

          “We are disappointed the trial did not meet its primary endpoint given the significant unmet need in patients with negative symptoms of schizophrenia,” said Acadia CEO Steve Davis, in a statement. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          DIEP, the 'gold standard' of breast reconstruction, is under threat
          DIEP, the 'gold standard' of breast reconstruction, is under threat

          AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

          read more
          Readout LOUD podcast: Venture capital turmoil, obesity drug competition
          Readout LOUD podcast: Venture capital turmoil, obesity drug competition

          Whyareaddictiontreatmentssohardtoget?Cansmallcompaniescompeteinobesity?Andsincewhenis“SeriesE”athing

          read more
          After affirmative action ruling, medical educators look to 'holistic review'
          After affirmative action ruling, medical educators look to 'holistic review'

          AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

          read more

          10 states plan to sue EPA over standards for residential wood

          DonSakischecksthefireinhisRitewaywoodstoveathishomeonJan.23,2018,inPalmer,Alaska.Sakisandhisfamilyha